FDA Issues Early Alert for GE HealthCare Infant Resuscitation Systems Due to Oxygen Blender Issue
Early Alert for GE HealthCare Infant Resuscitation Systems
The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain GE HealthCare infant resuscitation systems and warmers used in neonatal care settings.
The issue involves specific air-oxygen blenders used in affected devices. According to GE HealthCare, the blender knob shaft may loosen over time, potentially causing the delivered oxygen concentration to differ from the concentration selected by the user.
Because these systems are used to provide oxygen and ventilation support to infants during resuscitation and stabilization, inaccurate oxygen delivery could result in either hypoxia (insufficient oxygen) or hyperoxia (excessive oxygen exposure), both of which may pose significant risks to neonatal patients.
Affected Devices
The alert affects certain configurations of:
-
- Giraffe6 Stand-Alone Infant Resuscitation Systems
- Giraffe6 Warmers with Integrated Resuscitation Systems (iRes)
- Panda Warmers with Integrated Resuscitation Systems (iRes)
- Panda Freestanding Warmers
- Certain replacement blender assemblies (M1091607-R)
Healthcare facilities should review FDA and GE HealthCare communications to determine whether devices in service contain affected blender components.
Recommended Actions
GE HealthCare has advised customers to immediately inspect affected equipment and identify any units containing impacted blenders.
If an affected blender is identified, GE recommends removing the device from patient use until corrective actions can be completed.
For facilities that must continue using affected systems prior to correction, GE HealthCare recommends:
-
- Completing all pre-use inspection and checkout procedures before each patient use
- Performing the blender Multipoint Oxygen Concentration Check described in the service manual
- Frequently verifying oxygen concentration using an independent oxygen analyzer
- Removing any device from service if inspection or performance checks fail
Facilities should also evaluate spare inventory and quarantine affected replacement blenders.
Regulatory Perspective
The FDA’s Early Alert process is intended to rapidly communicate potentially serious device issues before the agency completes its full evaluation.
While no serious injuries or deaths have been reported as of May 20, 2026, the potential for inaccurate oxygen delivery in neonatal resuscitation settings elevates the significance of this issue. Neonates are particularly vulnerable to both under-oxygenation and over-oxygenation, making oxygen concentration accuracy a critical performance characteristic for these devices.
This alert serves as a reminder of the importance of preventive maintenance, pre-use verification testing, and robust equipment management programs for life-supporting and life-sustaining medical devices.
MDP Takeaway
Healthcare facilities using GE HealthCare neonatal warming and resuscitation systems should promptly identify affected devices, review GE HealthCare’s field action instructions, and verify that clinical engineering, respiratory therapy, and neonatal care teams are aware of the issue.
Given the critical nature of neonatal resuscitation equipment, organizations should ensure corrective actions are completed as quickly as possible and consider heightened monitoring of oxygen delivery performance until affected units are remediated.
MDP will continue monitoring FDA communications and provide updates as additional information becomes available.
Links
Read the FDA’s announcement here.
Download the List of Affected Products
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
FDA Investigates Cancer Risk with Zolgensma Gene Therapy
Postmarketing reports identify cases of tumor formation linked to gene therapy vector integration, prompting FDA to evaluate potential regulatory action.The U.S. Food and Drug Administration (FDA) is investigating a serious potential cancer risk associated with...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...